ES2218407T3 - Uso de oxazolidinonas tiamida para el tratamiento de la resorcion osea y la osteoporosis. - Google Patents

Uso de oxazolidinonas tiamida para el tratamiento de la resorcion osea y la osteoporosis.

Info

Publication number
ES2218407T3
ES2218407T3 ES01926589T ES01926589T ES2218407T3 ES 2218407 T3 ES2218407 T3 ES 2218407T3 ES 01926589 T ES01926589 T ES 01926589T ES 01926589 T ES01926589 T ES 01926589T ES 2218407 T3 ES2218407 T3 ES 2218407T3
Authority
ES
Spain
Prior art keywords
osteoporosis
treatment
oxazolidinones
tiamida
resortion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES01926589T
Other languages
English (en)
Inventor
Gebre-Mariam Mesfin
Richard K. Jensen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co, Upjohn Co filed Critical Pharmacia and Upjohn Co
Application granted granted Critical
Publication of ES2218407T3 publication Critical patent/ES2218407T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Abstract

El uso de una cantidad efectiva de un compuesto de **fórmula** o las sales farmacéuticamente aceptables del mismo para preparar un medicamento para tratar o prevenir osteoporosis, resorción ósea u otra enfermedad ósea en un mamífero vertebrado en la que: R1 es a) H, b) NH2, c) NH-alquiloC1-4, d) alquiloC1-4, e) -OalquiloC1-4, f) -SalquiloC1-4, g) alquiloC1-4 sustituido con 1-3 F, 1-2 Cl, CN o ¿COOalquiloC1-4, h) cicloalquiloC3-6, i) N(alquiloC1-4)2 o j) N(CH2)2-5; A es un residuo heteroaromático de 5 miembros que tiene de uno a tres átomos seleccionados del grupo constituido por S, N, y O, en el que el residuo heteroaromático de 5 miembros se une por medio de un átomo de carbono, en el que el residuo heteroaromático de 5 miembros puede tener adicionalmente un anillo benceno o naftilo fusionado en él, en el que el residuo heteroaromático de 5 miembros está sustituido opcionalmente con de uno a tres R48.
ES01926589T 2000-04-20 2001-04-17 Uso de oxazolidinonas tiamida para el tratamiento de la resorcion osea y la osteoporosis. Expired - Lifetime ES2218407T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19868800P 2000-04-20 2000-04-20
US198688P 2000-04-20

Publications (1)

Publication Number Publication Date
ES2218407T3 true ES2218407T3 (es) 2004-11-16

Family

ID=22734385

Family Applications (1)

Application Number Title Priority Date Filing Date
ES01926589T Expired - Lifetime ES2218407T3 (es) 2000-04-20 2001-04-17 Uso de oxazolidinonas tiamida para el tratamiento de la resorcion osea y la osteoporosis.

Country Status (14)

Country Link
US (1) US20020010341A1 (es)
EP (1) EP1274426B1 (es)
JP (1) JP2003531167A (es)
AT (1) ATE264101T1 (es)
AU (2) AU5311301A (es)
CA (1) CA2405543A1 (es)
DE (1) DE60102812T2 (es)
DK (1) DK1274426T3 (es)
ES (1) ES2218407T3 (es)
NZ (1) NZ522080A (es)
PT (1) PT1274426E (es)
TR (1) TR200401141T4 (es)
WO (1) WO2001080841A2 (es)
ZA (1) ZA200208269B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2841472B1 (fr) * 2002-06-28 2006-02-24 Agronomique Inst Nat Rech Composition nutritionnelle ou therapeutique contenant le compose hesperidine ou l'un de ses derives
FR2853549B1 (fr) * 2003-04-11 2007-11-09 Agronomique Inst Nat Rech Composition nutritionnelle ou therapeutique contenant le compose oleuropeine ou l'un de ses derives
EP1874782A1 (en) 2005-04-15 2008-01-09 Ranbaxy Laboratories Limited Oxazolidinone derivatives as antimicrobials
DK1899331T3 (da) 2005-06-29 2010-03-08 Pharmacia & Upjohn Co Llc Homomorpholinoxazolidnoner som antibakterielle midler
WO2008021338A2 (en) 2006-08-15 2008-02-21 Wyeth Tricyclic oxazolidone derivatives useful as pr modulators
FR3005419B1 (fr) 2013-05-13 2015-09-04 Agronomique Inst Nat Rech Utilisation d'une association de deux composes pour le traitement et/ou la prevention de troubles osseux
FR3066919B1 (fr) 2017-06-06 2019-08-02 Institut National De La Recherche Agronomique (Inra) Composition de phycocyanine pour son utilisation pour inhiber la resorption osseuse.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2123889T3 (es) * 1994-11-02 1999-01-16 Merck Patent Gmbh Antagonistas de receptores de adhesion.
DE19516483A1 (de) * 1995-05-05 1996-11-07 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
ES2242280T3 (es) * 1997-05-30 2005-11-01 PHARMACIA & UPJOHN COMPANY LLC Agentes antibacterianos de oxazolidinona que contienen funcionalidad tiocarbonilo.

Also Published As

Publication number Publication date
EP1274426A2 (en) 2003-01-15
ATE264101T1 (de) 2004-04-15
NZ522080A (en) 2004-04-30
WO2001080841A3 (en) 2002-04-04
DK1274426T3 (da) 2004-06-21
AU5311301A (en) 2001-11-07
AU2001253113B2 (en) 2005-02-03
WO2001080841A2 (en) 2001-11-01
PT1274426E (pt) 2004-08-31
EP1274426B1 (en) 2004-04-14
DE60102812D1 (de) 2004-05-19
US20020010341A1 (en) 2002-01-24
TR200401141T4 (tr) 2004-07-21
JP2003531167A (ja) 2003-10-21
CA2405543A1 (en) 2001-11-01
ZA200208269B (en) 2004-02-11
DE60102812T2 (de) 2005-06-16

Similar Documents

Publication Publication Date Title
BR0317715A (pt) Composições e processos de uso de collajolie
DE60213762D1 (de) Implementierung des SHA1 Algorithmusses
MXPA03007140A (es) Derivados de carbolina.
BR0212924A (pt) Inibidores de glicogênio sintase quinase-3 (gsk-3) para o tratamento de glaucoma
BR0215405A (pt) Composições e processos de uso de collajolie
MXPA03001789A (es) Composiciones para el cuidado de telas que comprenden silicones cationicos y metodos que emplean las mismas.
EE05507B1 (et) Rosuvastatiini ZD4522) kasutamine heterosgootseperekondliku hperkolesteroleemia raviks
CL2009001279A1 (es) Compuestos derivados de nociceptina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor (sol. divisional 2103-03).
EP1446445A4 (en) PORENCIL FOR ORTHOPEDIC CEMENT
DK1377245T3 (da) Immunstimulerende belægning af kirurgiske indretninger
DE60216233D1 (en) Carbolinderivate
PT1446458E (pt) Adesivos para colagem de elastomeros endurecidos com peroxido
BR0107667A (pt) Composto de linezolida em forma de cristal que e farmaceuticamente útil como agente antibacteriano e método de preparação do mesmo
BR0014560B1 (pt) uso de uma composiÇço de tratamento de tecidos.
UY27203A1 (es) Bencimidazoles útiles en el tratamiento de la disfunción sexual
ECSP034866A (es) Combinaciones antineoplásticas
BR0210101A (pt) Combinações antineoplásticas
ES2218407T3 (es) Uso de oxazolidinonas tiamida para el tratamiento de la resorcion osea y la osteoporosis.
ATE302776T1 (de) Kondensierte pyridoindolderivate
IT1306165B1 (it) Impiego di inibitori della sostanza p per il trattamento degliadenocarcinomi.
AR028620A1 (es) Combinacion de secretagogos de hormona del crecimiento y antidepresivos
BR0210632A (pt) Tratamento de doença parasìtica
HUP0302738A2 (hu) SARP-1 alkalmazása scleroderma kezelésére és megelőzésére
IT1289154B1 (it) Derivati di isoflavone loro preparazione e loro impiego terapeutico
GT200000114A (es) Forma cristalina iii de la n-(4-(5-dimetilaminoftalen-1-sulfonilamino) fenil)-3-hidroxi-2, 2-dimetilpropionamida.